187341-93-1Relevant academic research and scientific papers
Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections
Zhu, Tianbao,Chen, Xi,Li, Chenglan,Tu, Jie,Liu, Na,Xu, Defeng,Sheng, Chunquan
supporting information, (2021/05/19)
Invasive fungal infections remain a challenge due to lack of effective antifungal agents and serious drug resistance. Discovery of antifungal agents with novel antifungal mechanism is important and urgent. Previously, we designed the first CYP51/HDAC dual
Triazole CYP51-HDAC double-target antifungal compound as well as preparation method and application thereof
-
Paragraph 0188-0191, (2020/07/15)
The invention discloses a triazole CYP51-HDAC double-target antifungal compound, which has a structural general formula disclosed in the invention, wherein R is selected from one of the structures disclosed in the invention. According to the triazole CYP5
Antileukotrienic N-arylethyl-2-arylacetamides in the treatment of ulcerative colitis
Junek, Richard,Brunova, Bohumila,Kverka, Miloslav,Panajotova, Vladimira,Jandera, Antonin,Kuchar, Miroslav
, p. 1084 - 1094 (2008/03/13)
A series of arylacetic acid derivatives bearing methyl(arylethyl)amino groups were prepared and their antileukotrienic activities involving LTB4 were evaluated. Regression analysis has shown a strong dependence of these activities on lipophilic
Synthesis and biological evaluation of phenylacetyl derivatives having low central nervous system permeability as potent and selective M2 muscarinic receptor antagonists
Watanabe, Toshihiro,Kakefuda, Akio,Tanaka, Akihiro,Takizawa, Kenji,Hirano, Seiko,Shibata, Hiroshi,Yamagiwa, Yoko,Yanagisawa, Isao
, p. 53 - 68 (2007/10/03)
A series of phenylacetyl derivatives containing the 5,10-dihydro-11H- dibenzo[b,e][1,4]diazepin-11-one or 5,11-dihydro-6H-pyrido[2,3- b][1,4]benzodiazepin-6-one skeleton was prepared and evaluated for their binding affinities to muscarinic receptors in vitro and for antagonism of bradycardia, salivation and tremor in vivo. Among them, compounds 56 and 66 had high affinity for M2 muscarinic receptors in the heart (pK(i) = 8.7 and 8.9, respectively) with low affinity for M3 muscarinic receptors in the submandibular gland. A structure-activity relationship (SAR) study suggested that the high M2 selectivity over the M3 muscarinic receptors of 56 may be attributed to the direction of the carboxamide carbonyl group. In in vivo studies, 56 and 66 antagonized oxotremorine-induced bradycardia in rats on both intravenous and oral administration, and their heart rate increasing effect in dogs with nocturnal bradycardia was about 3-fold greater than that of AF-DX 116. Furthermore, they had almost no influence on oxotremorine- induced tremor in mice, presenting no evidence of central transfer.
